Skip to main content
SpringerLink
Log in

ACE-Inhibition for Secondary Prevention of Cardiovascular Events—Should We Change Our Recommendation After PEACE?

  • Editorial
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Voors AA, Van Velduisen DJ, Van Gilst WH. The current role of ACE-inhibitors for secondary prevention; from pathogenesis to clinical practice CITATION this issue.

  2. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE trial investigators.angiotensin-converting-enzyme in stable coronary artery disease. N Engl J Med 2004;351:2058–2068.

    Article  CAS  PubMed  Google Scholar 

  3. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): Case-control study. Lancet 2004;364:937–952.

    Article  PubMed  Google Scholar 

  4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: Systematic review and meta-annalysis. BMJ 2003;326:1423.

    Article  CAS  PubMed  Google Scholar 

  5. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;28;326:1427.

    Article  Google Scholar 

  6. Heart outcomes prevention evaluation investigators effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcome prevention evaluation study investigators. N Engl J Med 2003;342:145–153.

    Article  Google Scholar 

  7. EUROPA Investigatos Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788.

    Article  Google Scholar 

  8. Oubina MP, de las Heras N, Cediel E, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atheroscleroticrabbits. ClinSci(Lond) 2003;105:655–662.

    CAS  Google Scholar 

  9. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effects of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781–788.

    Article  CAS  PubMed  Google Scholar 

  10. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670–1676.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair of Cardiology, University of Ferrara, Corso Giovecca 203, 44100, Ferrara

    Roberto Ferrari MD

  2. Chair of Cardiology, University of Ferrara, Corso Giovecca 203, 44100, Ferrara

    Roberto Ferrari MD

Authors
  1. Roberto Ferrari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Ferrari MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrari, R. ACE-Inhibition for Secondary Prevention of Cardiovascular Events—Should We Change Our Recommendation After PEACE?. Cardiovasc Drugs Ther 20, 11–12 (2006). https://doi.org/10.1007/s10557-006-7297-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-006-7297-8

Search

Navigation